Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…Abstract Number: 1724 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
Background/Purpose: To analyze the effectiveness and safety of rituximab (RTX) for the treatment of refractory systemic sclerosis (SSc)–associated calcinosis. Methods: We undertook an observational study…Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…Abstract Number: 2692 • 2017 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment
Vitamin D Deficiency In Systemic Sclerosis Patients: Relations With Multiple Clinical Parameters and Standard TreatmentBackground/Purpose : In SSc patients, low 25-hydroxyvitamin D (25(OH)D) serum concentrations have…Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…Abstract Number: 2069 • 2016 ACR/ARHP Annual Meeting
Dipeptidyl-Peptidase-4 (DPP4) Positive Fibroblast Subpopulation Promotes Fibrosis and Are a Molecular Target for Treatment of Fibrosis
Background/Purpose: Dipeptidyl-peptidase-4 (DPP4) has been recently shown to identify a distinct dermal lineage with intrinsic fibrogenic potential and its targeted inhibition leads to reduced scar…Abstract Number: 2888 • 2016 ACR/ARHP Annual Meeting
Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease in which the damage of microcirculation is critical to develop the disease. In SSc, vascular complications…Abstract Number: 2913 • 2016 ACR/ARHP Annual Meeting
Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients
Background/Purpose: In systemic sclerosis (SSc), microvascular damage progresses from capillary dilation to capillary loss and reactive angiogenesis, as detectable by nailfold videocapillaroscopy (NVC) [1]. The…Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…Abstract Number: 1896 • 2016 ACR/ARHP Annual Meeting
Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Background/Purpose: Survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), especially systemic sclerosis (SSc), is poorer than that of patients…Abstract Number: 848 • 2015 ACR/ARHP Annual Meeting
Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease, commonly associated with Raynaud phenomenon (RP). The aim of this study was to characterize the microvascular…Abstract Number: 1879 • 2015 ACR/ARHP Annual Meeting
Immunosuppressive “Routine”� Treatment of SSc Patients with Limited Cutaneous Involvement and Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) represents one of the most frequent causes of death in systemic sclerosis (SSc) patients. Yet, there are no approved drugs…